← SynDRA
ISONIAZID
SynDRA canonical compound SYN0000326 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | CYP3A4 |
| Mechanism of action | Enoyl-acyl-carrier protein reductase inhibitor |
| Indication | tuberculosis |
| Disease area | infectious disease |
All known targets
- CYP3A4
- CYP1A2
- CYP2C19
- CYP2C8
- CYP2E1
- Bact inhA
- CYP3A5
- MPO
- folA
- inhA
- katG
Mechanisms of action (all sources)
- Cyclooxygenase inhibitor
- Enoyl-acyl-carrier protein reductase inhibitor
- FABI inhibitor
- Bact inhA INHIBITOR
- inhA INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB1
- KDM4E
- NPY1R
- NEIL1
- MMP9
- MMP1
- MLNR
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LCK
- KCNH2
- NR1I2
- KAT2A
- HTR7
- HTR6
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- HMGCR
- HDAC6
- NPY2R
- NR3C1
- GLS
- PTPRC
- TBXAS1
- TBXA2R
- TACR2
- TACR1
- SLCO2B1
- SLCO1B3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- AHR
- CP1A2
- CP2C9
- CP2CJ
- CP2D6
- CP3A4
- MDR1
- RARA
Drug classes
- Antimycobacterial
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antimetabolites
- Antitubercular Agents
- Fatty Acid Synthesis Inhibitors
- Hypolipidemic Agents
ATC classes
- J04A · DRUGS FOR TREATMENT OF TUBERCULOSIS
Cross-references
Synonyms
- DOW-ISONIAZID
- HYZYD
- INH
- LANIAZID
- NYDRAZID
- RIFAMATE
- RIFAMPIN AND ISONIAZID
- RIFATER
- RIMIFON
- STANOZIDE
- 4-Pyridinecarboxylic hydrazide
- armazid
- isoniazide
- isonicotinohydrazide
- Isoniazide
- Isoniazida
- Armazid
- Armazide
- Atcotibine
- Cedin
- Cotinazin
- Dianicotyl
- Eralon
- Ertuban
- Hidrasonil
- Hydrazid
- Ipcazide
- Iscotin
- Isidrina
- Isobicina
- Isoniazidum
- Isonicotan
- Mybasan
- Neumandin
- Teebaconin
- Tisiodrazida
- NSC-9659
Reported adverse events
- Nausea
- Agranulocytosis
- Hypersensitivity
- Cerebellar syndrome
- Stevens-Johnson syndrome
Look up ISONIAZID in the interactive SynDRA portal →